Bayer: Carcinoma, Renal Cell trials

The registry lists 29 Carcinoma, Renal Cell studies with Bayer as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 10Phase 3 4Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been CompletedCompletedNCT03890731Phase 2Results posted
• A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.TerminatedNCT00678288Phase 2Results posted
• A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCCCompletedNCT00664326Phase 2Results posted
• Sorafenib Dose Escalation in Renal Cell CarcinomaCompletedNCT00618982Phase 2Results posted
• Long-term Extension From RCC Phase II (11515)CompletedNCT00586495Phase 2Results posted
• Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)CompletedNCT00586105Phase 3Results posted
• BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell CarcinomaCompletedNCT00117637Phase 2Results posted
• Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell CancerCompletedNCT00073307Phase 3Results posted
• A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1
• Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell CarcinomaCompletedNCT01982097
• Sorafenib in Elderly mRCCCompletedNCT01728948
• Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell CarcinomaCompletedNCT01585974
• Nexavar Dosing in Renal Cancer Patients in "Real-life" SettingCompletedNCT01557127
• Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT01508364
• Nexavar Post-marketing Surveillance for RCC in Japan: Early Access ProgramCompletedNCT01412671
• Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in JapanCompletedNCT01411423
• Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney CancerWithdrawnNCT01353794
• Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based TherapyTerminatedNCT01195649
• Regulatory Post Marketing Surveillance Study on Nexavar®CompletedNCT01012011
• Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With NexavarCompletedNCT00895674
• A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®CompletedNCT00771147
• BAY43-9006 Phase II Study for Renal Cell CarcinomaCompletedNCT00661375Phase 2
• Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.TerminatedNCT00622479Phase 1
• An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT00492986Phase 3
• Phase IV Randomization to On-Going Treatment to Evaluate Sustained SorafenibTerminatedNCT00352859Phase 4
• Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell CarcinomaCompletedNCT00111020Phase 3
• Research Study for Patients With Metastatic Renal Cell CarcinomaTerminatedNCT00110344Phase 2
• Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory CancerCompletedNCT00079612Phase 2
• Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell CarcinomaCompletedNCT00044564Phase 2